- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
The chief executive of AlphaRx , Michael Lee, announced In a U.S. Securities and Exchange Commission filing, that he has concluded his purchase of 1,000,000 shares of his company for an average price of $0.17, increasing his holdings to about 11,327,866 shares or 13% of the company. Lee said following the purchase "I strongly believe that our share price is severely undervalued given the progress we have demonstrated in our Nanotechnology Drug Delivery Platform." 'Vansolin', Lee noted, intended for the treatment of noscomial pneumonia, is now on track to enter into human trials in 2008 and has a potential market value of US$3.6 billion. Lee concluded his comments by saying "we have four Nano products in the development pipeline with an estimated annual market sales potential of over US$6.0 billion dollars."
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
For more information, please click here
168 Konrad Crescent
Suite 200, Markham
Ontario, Canada L3R 9T9
Director, Market & Business Development
Copyright © PR Newswire Association LLC.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Nanoscale Trojan horses treat inflammation May 24th, 2016
Doubling down on Schrödinger's cat May 27th, 2016
Deep Space Industries and SFL selected to provide satellites for HawkEye 360’s Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016